Additional value of FDG-PET to contrast enhanced-computed tomography (CT) for the diagnosis of mediastinal lymph node metastasis in non-small cell lung cancer: a Japanese multicenter clinical study
- First Online:
This study was a controlled multicenter clinical study to verify the diagnostic effects of additional FDG-PET to contrast-enhanced CT for mediastinal lymph node metastasis in patients with operable non-small cell lung cancer (NSCLC).
NSCLC patients with enlarged mediastinal lymph nodes (short diameter, 7–20 mm), confirmed using contrast-enhanced CT, were examined using FDG-PET to detect metastases prior to surgery. The primary endpoint was the accuracy for concomitantly used CT and FDG-PET showing the additional effects of FDG, compared with CT alone. The secondary endpoints were the clinical impact of FDG-PET on therapeutic decisions and adverse reaction from FDG administration. The images were interpreted by investigators at each institution. Moreover, blinded readings were performed by an image interpretation committee independent of the institutions. The gold standard was the pathological diagnosis determined by surgery or biopsy after PET, and patients in whom a pathological diagnosis was not obtained were excluded from the analysis.
Among 99 subjects, the results for 81 subjects eligible for analysis showed that the accuracy improved from 69.1% (56/81) for CT alone to 75.3% (61/81) for CT + PET (p = 0.404). These findings contributed to treatment decisions in 63.0% (51/81) of the cases, mainly with regard to the selection of the operative procedure. The results of the image interpretation committee showed that the accuracy improved from 64.2% (52/81) (95% CI 52.8–74.6) for CT to 75.3% (61/81) (95% CI 64.5–84.2) for CT + PET. The accuracy for 106 mediastinal lymph nodes improved significantly from 62.3% (66/106) (95% CI 52.3–71.5) for CT to 79.2% (84/106) (95% CI 70.3–86.5) for CT + PET (p < 0.05). We found that no serious adverse drug reactions appeared in any of the 99 patients who received FDG, except for transient mild outliers in the laboratory data for two patients.
The addition of FDG-PET to contrast-enhanced CT imaging for the staging of NSCLC improved the diagnostic accuracy for mediastinal lymph node metastasis. FDG-PET improved the precision of the staging of NSCLC and contributed to the surgical decisions.
KeywordsMediastinal lymphnode Lymphnode metastasis Non-small cell lung cancer FDG-PET CT
- 4.The American Thoracic Society and The European Respiratory Society. Pretreatment evaluation of non-small-cell lung cancer. Am J Respir Crit Care Med. 1997;156:320–32.Google Scholar
- 9.Vansteenkiste JF, Stroobants SG, De Leyn PR, Dupont PJ, Verschakelen JA, Nackaerts KL, et al. Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer: a prospective analysis of 50 cases. Leuven Lung Cancer Group. Chest. 1997;112:1480–6.PubMedCrossRefGoogle Scholar
- 14.Standard of compounds labeled with positron nuclides approved as established techniques for medical use (by Subcommittee on Medical Application of Cyclotron-Produced Radionuclides), 1999 revision. Radioisotopes. 1999;48(12):i-xxviGoogle Scholar
- 20.van Baardwijk A, Bosmans G, Boersma L, Buijsen J, Wanders S, Hochstenbag M, et al. PET–CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes. Int J Radiat Oncol Biol Phys. 2007;68:771–8.PubMedCrossRefGoogle Scholar
- 22.FDA guidance for industry developing medical imaging drugs and biological products. Part 3: design, analysis, and interpretation of clinical studies. 2004.Google Scholar
- 23.Guidelines on clinical evaluation of radioactive diagnostics. Japanese Society of Nuclear Medicine. 2005.Google Scholar
- 24.Reed CE, Harpole DH, Posther KE, Woolson SL, Downey RJ, Meyers BF, et al. Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2003;126:1943–51.PubMedCrossRefGoogle Scholar